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1 
Abstract 1 
Objective: To assess the value of positive family history (FH) as a risk factor for prostate 2 
cancer (PCa) incidence and grade among men undergoing organized PSA-screening in a 3 
population-based study. 4 
Patients and Methods: The study cohort comprised all attendees of the Swiss arm of the 5 
ERSPC with systematic PSA-tests every 4 years. Men reporting first-degree relative(s) 6 
diagnosed with PCa were considered to have a positive FH. Biopsy was exclusively PSA-7 
triggered with a threshold of 3ng/ml. Primary endpoint was PCa diagnosis. Kaplan-Meier 8 
and Cox regression analyses were used. 9 
Results: Of 4,932 attendees with a median age of 60.9 (IQR 57.6-65.1) years, 334 (6.8%) 10 
reported a positive FH. Median follow-up duration was 11.6 years (IQR 10.3-13.3). 11 
Cumulative PCa incidence was 60/334 (18%, positive FH) and 550/4598 (12%, negative 12 
FH) (OR 1.6, 95%CI 1.2-2.2, p=0.001), respectively. In both groups, most PCa diagnosed 13 
had a low grade. There were no significant differences of PSA at diagnosis, biopsy 14 
Gleason score or Gleason score on pathologic specimen among men who underwent 15 
radical prostatectomy between both groups, respectively. On multivariable analysis, age 16 
(HR 1.04, 95% CI 1.02-1.06), baseline PSA (HR 1.13 95% CI 1.12-1.14), and FH (HR 1.6, 17 
CI 1.24-2.14) were independent predictors for overall PCa incidence (p<0.0001 each). 18 
Only baseline PSA (HR 1.14, 95%CI 1.12-1.16, p<0.0001) was an independent predictor 19 
of Gleason score ≥7 PCa on prostate biopsy. The proportion of interval PCa diagnosed in 20 
between the screening rounds was non-significantly different.  21 
Conclusion: Irrespective of the FH status, the current PSA-based screening setting 22 
detects the majority of aggressive PCa and missed only a minority of interval cancers with 23 
a 4-year screening algorithm. Our results suggest that men with a positive FH are at 24 
increased risk for low grade but not aggressive PCa. For personalized PCa early 25 
detection, more details of the relative`s cancer characteristics might need to be collected 26 
2 
to better estimate the cancer biology. 27 
3 
Introduction 28 
With an annual incidence of 233’000 in the United States [1] and 382’000 in Europe 29 
[2] prostate cancer (PCa) presents a major health issue. Population-based screening with 30 
prostate-specific antigen (PSA) has been shown to reduce cancer-specific mortality [3]. 31 
However, the main drawback of mass screening is the high rate of overdiagnosis of 32 
approximately 50% [4]. Overdiagnosis implies that the cancer detected by screening would 33 
have never become harmful during a man`s lifetime. One reason for this is the high 34 
prevalence of undiagnosed PCa shown in autopsy studies which indicates a partly low-35 
aggressive biology [5]. Similarly, in population-based screening studies, the majority of 36 
detected PCa have low risk feature [3] most of which harbour a negligible risk to 37 
metastasize [6]. Ideally, these low-risk PCa should remain undetected which points at the 38 
need of risk-stratified screening [7].  39 
 40 
Current urologic guidelines consider FH a strong risk factor for PCa [8, 9]. Evidence 41 
for this comes from a large twin study, showing that a positive FH is an important risk 42 
factor for future PCa development, particularly in men who have first-degree relatives 43 
affected from PCa [10]. Several other studies have confirmed FH as a risk factor of PCa 44 
[11, 12]. However, most data on this topic were collected from population registers before 45 
or at the beginning of the PSA-screening era evaluating clinically diagnosed PCa while 46 
nowadays, opportunistic PSA-screening is increasing in Western countries [13, 14]. This in 47 
turn, has led to a shift towards more localized disease and therefore dramatically changed 48 
the face of PCa in terms of a sharp increment in incidence and stage migration over the 49 
past decades [15]. 50 
There is controversial data on whether FH has an effect on cancer aggressiveness 51 
[16]. For instance, FH was an independent predictor for biochemical relapse only in the 52 
early PSA era whereas men diagnosed later on presented with more favourable cancer 53 
4 
characteristics [17]. Moreover, the relative risk for men with a FH for PCa decreased 54 
throughout the pre-PSA era suggesting a stage migration [18].  We hypothesized that due 55 
to the increasing screening attitude with detection of particularly low-risk disease at an 56 
earlier stage, FH might have a reduced effect on PCa incidence. Therefore, we analysed 57 
this risk factor in our screening study with an organized screening schedule where PSA-58 
screening and subsequent biopsy were performed exclusively upon PSA-values ≥3ng/ml. 59 
We hypothesize that a positive FH is not associated with aggressive PCa due to the effect 60 
of organized PSA-screening. 61 
 62 
 63 
 64 
 65 
 66 
 67 
 68 
 69 
 70 
 71 
 72 
 73 
 74 
 75 
 76 
 77 
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Materials and Methods 78 
This study was conducted within the European Randomized Study of Screening for 79 
Prostate Cancer (ERSPC) – Switzerland. The study protocol and the population have been 80 
described previously[19]. From September 1998 to August 2003, 10’311 Swiss men aged 81 
55-70 years were randomized 1:1 to the screening or control group, respectively. 82 
Randomization was done after informed consent. From a total of 5129 eligible men 83 
randomized to the screening arm, 4’932 (96.2%) men underwent baseline PSA-screening 84 
and were included for further analysis. In accordance with the main protocol of the ERSPC 85 
[20] a 6 core transrectal ultrasound guided lateralized prostate biopsy (or 8 core if prostate 86 
volume was >40cc) was performed if the PSA-value was ≥3.0ng/ml. Biopsy was 87 
exclusively PSA-driven as per study protocol and not performed upon positive FH. PSA-88 
screening was continued every four years until the age of 75. In a side study, men with 89 
baseline PSA of 1-3ng/ml and free-to-total ratio ≤20% were also offered prostate biopsy at 90 
baseline (1998-2003) [21]. We also analyzed the rate of cancers emerging clinically 91 
between the screening visits. These PCa were diagnosed outside the screening protocol 92 
either by opportunistic screening, by transurethral resection of the prostate or clinically, 93 
when the diagnosis was missed by organized PSA-screening. This type of cancer was 94 
termed "Interval PCa".  95 
 96 
All prostate biopsies were externally reviewed by an experienced uro-pathologist at the 97 
University Hospital Basel, Switzerland. Through periodic linkage of all men with the cancer 98 
registries, complete information on cancer incidence was obtained until December 2012. 99 
Several committees of the ERSPC accounted for the surveillance and quality of the data 100 
such as Epidemiology Committee, Pathology Committee, PSA Committee, Quality Control 101 
Committee, Causes of Death Committee with an independent Data Monitoring Committee. 102 
The Scientific Committee had access to the data and kept overview at any time [20]. PCa 103 
6 
risk was stratified according to the D’Amico classification [22]. Aggressive PCa was 104 
defined as Gleason score ≥ 7 PCa.  105 
 106 
Statistics 107 
Comparisons between patient characteristics for men with positive and negative FH 108 
were made using the Chi square test for proportions and Mann-Whitney U-test for 109 
continuous variables. Univariable and multivariable Cox regression analysis was used to 110 
examine the relationship between FH and time to PCa diagnosis during follow-up, with 111 
age, FH and baseline PSA-value as covariates. Kaplan-Meier curves were used to 112 
estimate the cancer-free survival function.  113 
The Statistical Package for Social Sciences (SPSS) version 20 (IBM Corporation, NY, 114 
USA) was used. All tests were two-sided with a significance level set at 0.05. The local 115 
ethical committee approved the study protocol. 116 
 117 
Self-reported data 118 
A standardized, non-validated questionnaire including FH on first and second 119 
degree relatives affected from PCa as well as International Prostate Symptom Score 120 
(IPSS) amongst other parameters was mailed up-front (prior to PSA-testing) to all 121 
attendees. In addition at each screening visit, all attendees underwent a structured 122 
personal interview by a trained study nurse who verified the reported data. Men who 123 
reported one or more first-degree relative(s) (father or brother) diagnosed with PCa were 124 
considered as having a positive FH.  125 
 126 
 127 
 128 
 129 
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Results 130 
 131 
Clinical characteristics of 4932 attendees at baseline 132 
All men gave information about their relatives (response rate 100%). Overall, 334 133 
(6.8%) reported a positive FH. Most men had their father affected, n=242 (72.5%) while 134 
n=70 (21%) had brother(s) affected from the disease (table 1). Interestingly, the baseline 135 
IPSS score was higher in men with a positive FH (median 6 [IQR 3-10] vs. 5 [3-9], 136 
p<0.0001) (table 2). PSA at baseline was comparable between both groups. PSA-velocity 137 
at follow-up visit after 4 years was significantly higher in men with positive FH 138 
(0.32ng/ml/year vs 0.19ng/ml/year. p=0.05). This significant difference disappeared during 139 
follow-up visit 8 years from baseline (0.07ng/ml/year vs 0.06ng/ml/year; p=0.8). When PSA 140 
converted to values ≥3ng/ml, biopsy compliance was comparable between both groups 141 
(77.8% [negative FH] vs. 77.3% [positive FH], respectively).  142 
  143 
 144 
PCa incidence and cancer characteristics among men with positive vs. negative FH 145 
During a median follow-up duration of 11.6 years (IQR 10.3-13.3), more men with 146 
positive FH (18.0%) had been diagnosed with PCa as compared to men with negative FH 147 
(12.0%) (unadjusted OR 1.61, 95%CI 1.20-2.16; p=0.001). In case of PCa diagnosis, age 148 
at diagnosis and Gleason score were not significantly different between both groups (table 149 
2 and 3).  150 
Of 334 men with positive FH, 17 (5.1%) were found to have aggressive disease defined as 151 
a Gleason score of >=7 as compared to 183 of 4598 (4.9%) men with negative FH (OR 152 
1.30; 95%CI 0.77-2.15; p=0.3) (table 3). Seven (1.3%) men with negative FH were found 153 
to have metastasis at the time of diagnosis (none in the positive FH group). Three of 334 154 
8 
(0.9%) and 14 (0.3%) of 4598 died from PCa during follow-up (OR 2.97; 95% CI 0.85-155 
10.38, p=0.07). In case of radical prostatectomy (n=334), Gleason score, T-stage and 156 
frequency of positive lymph nodes were not significantly different between both groups 157 
(table 4). 158 
Incidence of interval PCa 159 
Interval PCa were diagnosed outside the screening protocol either by opportunistic 160 
screening, by TUR-P or clinically, when the diagnosis was missed by organized PSA-161 
screening. During the entire follow-up period, 156 cancers (3.2%) surfaced in between the 162 
screening rounds or after termination of screening due to age >75 years and were 163 
therefore termed interval cancer. Of those, 14 (4.2%) PCa emerged among men with 164 
positive FH and 142 (3.1%) among men with negative FH, respectively (OR 1.46, 95%CI 165 
0.83-2.56; p=0.2) (table 3). Biopsy Gleason scores of interval PCa were 3+3 (n=8 166 
[57.1%]), 3+4 (n=5 [35.7%]), 4+3 (n=1 [7.1%]), ≥4+4 (n=0[0%]) (positive FH) and 3+3 167 
(n=79 [55.6%]), 3+4 (n=31 [21.8%]), 4+3 (n=6 [4.2%]) and ≥4+4 (n=24 [16.9%] (negative 168 
FH), respectively (table 3). For 2 men, Gleason score could not be classified as diagnosis 169 
was achieved by clinical symptoms and PSA >100ng/ml. 170 
 171 
Risk factor analysis for the indidence of PCa 172 
Figures 1a and b show the cumulative incidence of overall (a) and aggressive (b) 173 
PCa, respectively, stratified by FH status. In multivariable analysis age, PSA and positive 174 
FH at baseline were all strong independent predictors for overall PCa detection during 175 
follow-up (Table 5a; p<0.0001 each). However, for time to aggressive PCa, only PSA at 176 
baseline (p<0.0001), but not FH (p=0.2) remained an independent predictor (Table 5b).  177 
 178 
 179 
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Discussion 180 
In the current study, men with positive FH had a higher unadjusted risk for overall 181 
PCa diagnosis as compared to men with negative FH (OR 1.61, 95%CI 1.20-2.16; 182 
p=0.001). The PCa detection rate among men with FH is comparable to previous reports 183 
although considerably below the calculated risk of former epidemiological studies of more 184 
than twice the risk [23]. The overall prevalence of FH of 6.8% in the Swiss cohort is in line 185 
with other series and appears to be representative [24-26]. When we adjusted for other 186 
parameters, a positive FH remained an independent predictor for overall, but not 187 
aggressive PCa. Importantly, the frequency of "interval PCa” indicating a more aggressive 188 
cancer biology was only slightly but not significantly higher in men with positive FH (4.2% 189 
vs 3.1%, OR 1.46; 95% CI 0.83-2.56, p=0.2 respectively). Thus, systematic PSA-screening 190 
with a 4 year algorithm seems to detect potentially aggressive PCa at an earlier stage. 191 
Without this organized screening schedule, we might expect more aggressive cases 192 
among men with positive FH as compared to negative FH as it was demonstrated in 193 
studies before the screening era [18]. However, the current screening attitude in the 194 
western world clearly drifts towards opportunistic screening with early retest intervals far 195 
below 4 years [13]. This intensive screening strategy seems to weaken the real predictive 196 
effect of a first-degree relative affected from PCa.  197 
 198 
Meta-analysis support the fact of having a first-degree relative diagnosed with PCa 199 
to be a significant risk factor for future PCa development to the index patient [27, 28]. This 200 
effect was particularly true for (clinically diagnosed) disease before the PSA-screening era. 201 
Reported risk ratios varied from 2.5 to 3.4 times as compared to men with negative FH 202 
with a greater number of family members affected or younger age at diagnosis increasing 203 
this risk even further [12]. Basically, a positive FH seems therefore to be a key factor to 204 
identify those individuals who have inherited predisposition to PCa and the goal of FH 205 
10 
inventory is to provide enough information for a risk assessment with respect to further 206 
investigations. However, the predominant part of the underlying data of those studies was 207 
gathered before or at the beginning of the PSA era. Having said that, some noteworthy 208 
contemporary studies have failed to reproduce the correlation between a positive FH and 209 
PCa aggressiveness [29]; for instance, the Prostate Cancer Prevention Trial found PSA-210 
levels, digital-rectal examination and previous biopsy but not positive FH as significant 211 
predictors for high grade disease despite a very high rate of positive FH of 17% [30]. 212 
However, a limitation of this study was the high rate of positive FH and the randomization 213 
of men with exclusively “low-risk” baseline PSA-values less or equally to 3ng/ml which 214 
does not reflect the characteristics of the general population.  215 
 216 
With the growing frequency of opportunistic PSA-based screening worldwide [13, 217 
14, 31], the PCa incidence increased rapidly and most of PCa are nowadays detected at 218 
an earlier stage and lower grade [15]. Mass screening is associated with an overdiagnosis 219 
rate of roughly 50% [4]. Every overdiagnosed PCa in turn induces a switch from negative 220 
to “falsely-positive” FH in relatives, which seems to dilute the true effect of FH on the 221 
biological aggressiveness of PCa. The results of the current study underline this effect. 222 
Whereas in early days, the odds for PCa was 2.5 to 3-fold higher in men having a 1st 223 
degree relative affected from PCa [12], it dropped to 1.6 in our trial or 1.3 in the Finnish 224 
arm of the ERSPC [26]. This slightly lower RR of 1.3 as compared to the current study can 225 
be explained by less intensive screening protocol in Finland as men in range 3-4 ng/ml 226 
underwent prostate biopsy only if free-to-total PSA ratio was less than 16%. There are still 227 
true hereditary PCa having shorter lead-time and an increased risk of developing an 228 
aggressive disease [32, 33]. However, in population-based studies, this proportion 229 
represents only a minority of all PCa diagnosed. Additionally, the only slightly higher 230 
percentage of aggressive PCa in the current study of 5.1% (positive FH) versus 231 
11 
4.0%(negative FH) suggests that at least a part of these cancers among men with a 232 
positive FH were detected in their pre-clinical development phase which is actually one of 233 
the very purposes of the screening intervention.  234 
While FH should still be considered as a risk factor in daily practice, the assessment 235 
should become much more sophisticated and detailed (e.g.  the exact origins of diagnosis, 236 
that is whether prostate cancer in relatives has been detected by PSA-screening or 237 
clinically; a detailed analysis of tumor characteristics;  the exact age at diagnosis of the 238 
first degree relative affected).  239 
Obviously, PCa diagnosis raises the awareness of the disease in family members as well 240 
as their GPs and thereby exposes male relatives to increased PSA testing and subsequent 241 
prostate biopsy. Also, a higher socioeconomic status was shown to be associated with 242 
detection of more localized but not metastatic PCa [34]. Thus, a percentage of men with a 243 
positive FH diagnosed with PCa are explained by increased screening behaviour.  244 
 245 
 246 
There are several limitations in our study: First, we did not have complete data on 247 
tumour characteristics among affected relatives, nor had we information on the three-248 
generation pedigree for more detailed FH evaluation. Second, we collected data on FH at 249 
the study entrance, but this might have changed slightly over time. Therefore, there might 250 
potentially be more men with a positive FH during follow-up. However, if so, this would 251 
weaken the impact of positive FH even more. Finally, we have a relatively small sample 252 
size as far as aggressive PCa is considered.  253 
It would be of interest to comparing those with a positive FH undergoing screening to 254 
those with a positive FH not undergoing screening (the control group of ERSPC). 255 
However, data on FH was not collected in the control group of our trial, so this interesting 256 
12 
question cannot be answered by the data. 257 
In conclusion, although our study has confirmed FH as a risk factor for PCa 258 
diagnosis, most of these men were classified as having low-risk disease in this 259 
contemporary population-based screening cohort. A PSA-based screening setting detects 260 
the majority of aggressive PCa and missed only a minority of interval cancers with a 4-year 261 
screening algorithm. FH as a risk factor might therefore rather be used complementary to 262 
risk factors such as prostate volume, baseline PSA and age. For a more personalized PCa 263 
early detection, information on a positive FH might need to be performed more detailed 264 
including complete information on cancer characteristics.  265 
 266 
 267 
 268 
 269 
 270 
 271 
 272 
 273 
 274 
 275 
 276 
 277 
 278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
 287 
 288 
13 
Acknowledgement: 289 
We thank Professor Lukas Bubendorf, Institute of Pathology, University Hospital Basel, 290 
Switzerland, for reviewing all prostate biopsies.  291 
 292 
 293 
 294 
 295 
Financial support ERSPC Switzerland: 296 
The Horten Foundation, Aargau Cancer League, Swiss Cancer League (Grant Nr KFS 297 
787-2-1999 and 01112-02-2001), Health Department of Canton Aargau, Prostate Cancer 298 
Research Foundation, Baugarten Foundation, Miss Messerli Foundation, Switzerland. 299 
Sigrid Carlsson is supported by a grant of AFA Insurance.  300 
 301 
Ethical standards: 302 
The study has been approved by the appropriate ethics committee 303 
 304 
Conflict of interest: 305 
 306 
Maciej Kwiatkowski is member of the advisory board at Astellas and has held a lecture at 307 
Myriad Genetics. 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
14 
References 321 
[1] Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for 322 
clinicians. 2014 Jan-Feb: 64:9-29 323 
[2] Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and 324 
mortality in Europe in 2008. European journal of cancer. 2010 Mar: 46:765-81 325 
[3] Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer 326 
mortality: results of the European Randomised Study of Screening for Prostate Cancer 327 
(ERSPC) at 13 years of follow-up. Lancet. 2014 Dec 6: 384:2027-35 328 
[4] Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-329 
specific antigen screening: estimates from the European Randomized Study of Screening 330 
for Prostate Cancer. Journal of the National Cancer Institute. 2003 Jun 18: 95:868-78 331 
[5] Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed 332 
prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer 333 
in the Prostate-Specific Antigen-Era. Int J Cancer. 2014 Dec 29:  334 
[6] Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do 335 
adenocarcinomas of the prostate with Gleason score (GS) </=6 have the potential to 336 
metastasize to lymph nodes? The American journal of surgical pathology. 2012 Sep: 337 
36:1346-52 338 
[7] Randazzo M, Beatrice J, Huber A, et al. Is further screening of men with baseline 339 
PSA < 1 ng ml worthwhile? The discussion continues-Results of the Swiss ERSPC 340 
(Aarau). Int J Cancer. 2015 Jan 6:  341 
[8] Heidenreich A BP, Bellmunt J. Guidelines on Prostate Cancer. 342 
2013:http://www.uroweb.org/guidelines/online-guidelines/?no_cache=1 343 
[9] Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA 344 
Guideline. J Urol. 2013 Aug: 190:419-26 345 
[10] Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in 346 
the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. 347 
N Engl J Med. 2000 Jul 13: 343:78-85 348 
[11] Frank C, Fallah M, Ji J, Sundquist J, Hemminki K. The population impact of familial 349 
cancer, a major cause of cancer. Int J Cancer. 2014 Apr 15: 134:1899-906 350 
[12] Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age-specific risk of incident 351 
prostate cancer and risk of death from prostate cancer defined by the number of affected 352 
family members. European urology. 2010 Aug: 58:275-80 353 
[13] Nordstrom T, Aly M, Clements MS, Weibull CE, Adolfsson J, Gronberg H. Prostate-354 
specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, 355 
Despite no recommendations for PSA screening: results from a population-based study, 356 
2003-2011. European urology. 2013 Mar: 63:419-25 357 
[14] Howard K, Brenner AT, Lewis C, et al. A comparison of US and Australian men's 358 
values and preferences for PSA screening. BMC health services research. 2013: 13:388 359 
[15] Glass AS, Cowan JE, Fuldeore MJ, et al. Patient demographics, quality of life, and 360 
disease features of men with newly diagnosed prostate cancer: trends in the PSA era. 361 
Urology. 2013 Jul: 82:60-5 362 
[16] Selkirk CG, Wang CH, Lapin B, Helfand BT. Family history of prostate cancer in men 363 
being followed by active surveillance does not increase risk of being diagnosed with high-364 
grade disease. Urology. 2015 Apr: 85:742-7 365 
[17] Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA. 366 
Aggressiveness of familial prostate cancer. J Clin Oncol. 2006 Jul 20: 24:3445-50 367 
[18] Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate 368 
cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 369 
2007 Oct 1: 121:1571-8 370 
[19] Kwiatkowski M, Huber A, Stamm B, et al. Features and preliminary results of 371 
prostate cancer screening in Canton Aargau, Switzerland. BJU international. 2003 Dec: 92 372 
15 
Suppl 2:44-7 373 
[20] Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of 374 
follow-up. N Engl J Med. 2012 Mar 15: 366:981-90 375 
[21] Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R. Prospective 376 
detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 377 
ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience. J Urol. 2001 378 
Sep: 166:851-5 379 
[22] D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical 380 
prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically 381 
localized prostate cancer. JAMA. 1998 Sep 16: 280:969-74 382 
[23] Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of 383 
prostate cancer. The New England journal of medicine. 2010 Apr 1: 362:1192-202 384 
[24] Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the 385 
prevalence of family history of cancer: implications for cancer screening and prevention. 386 
Genet Med. 2006 Sep: 8:571-5 387 
[25] Mai PL, Wideroff L, Greene MH, Graubard BI. Prevalence of family history of breast, 388 
colorectal, prostate, and lung cancer in a population-based study. Public Health Genomics. 389 
2010: 13:495-503 390 
[26] Saarimaki L, Tammela TL, Maattanen L, et al. Family history in the Finnish Prostate 391 
Cancer Screening Trial. Int J Cancer. 2015 May 1: 136:2172-7 392 
[27] Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate 393 
cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 394 
2003 Dec 10: 107:797-803 395 
[28] Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate 396 
cancer risk. BJU Int. 2003 Jun: 91:789-94 397 
[29] Thomas JA, 2nd, Gerber L, Moreira DM, et al. Prostate cancer risk in men with 398 
prostate and breast cancer family history: results from the REDUCE study (R1). Journal of 399 
internal medicine. 2012 Jul: 272:85-92 400 
[30] Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from 401 
the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute. 2006 Apr 402 
19: 98:529-34 403 
[31] Van der Meer S, Lowik SA, Hirdes WH, et al. Prostate specific antigen testing policy 404 
worldwide varies greatly and seems not to be in accordance with guidelines: a systematic 405 
review. BMC family practice. 2012: 13:100 406 
[32] Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT. A rare 8q24 single 407 
nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and 408 
possibly more aggressive disease. BJU international. 2015 Jan: 115:101-5 409 
[33] Beebe-Dimmer JL, Isaacs WB, Zuhlke KA, et al. Prevalence of the HOXB13 G84E 410 
prostate cancer risk allele in men treated with radical prostatectomy. BJU international. 411 
2014 May: 113:830-5 412 
[34] Bratt O, Garmo H, Adolfsson J, et al. Effects of prostate-specific antigen testing on 413 
familial prostate cancer risk estimates. J Natl Cancer Inst. 2010 Sep 8: 102:1336-43 414 
 415 
16 
Figure 1a Kaplan Meier estimate for PCa-free survival comparing positive vs negative FH 416 
Figure 1b Kaplan Meier estimate for aggressive PCa-free survival comparing positive vs 417 
negative FH  418 
 419 
